Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–8 of 8 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Intramuscular Auto Injector Clear all
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women

NCT02937766
View directory record Official record
Conditions
Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) in Healthy Post-menopausal Women
Interventions
Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 75 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.

NCT00319501
View directory record Official record
Conditions
Seizures, Epilepsies, Partial, Epilepsy, Complex Partial, Epilepsy, Generalized, Epilepsy
Interventions
Placebo, Vanquix Auto-Injector (Diazepam Injection)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
86
States / cities
Northport, Alabama • Little Rock, Arkansas • Irvine, California + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK/PD Study of IN-001 Sublingual Spray in Healthy Adults

NCT07210320
View directory record Official record
Conditions
Food Allergy, Anaphylaxis, Food Hypersensitivity, Food Allergy Peanut
Interventions
Epinephrine Auto-Injector 0.3 mg/0.3 mL, Epinephrine 0.3 mg intramuscular manual injection via a syringe and needle, IN-001 9.06 mg Sublingual Spray, IN-001 13.59 mg Sublingual Spray
Drug
Lead sponsor
Insignis Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals

NCT04207840
View directory record Official record
Conditions
Pharmacokinetics, Epinephrine, Albuterol, Asthma, Anaphylaxis
Interventions
Epinephrine (0.125 mg/inhalation), Epinephrine Injection Auto-Injector (0.3mg/0.3mL), Albuterol Sulfate (0.09 mg/inhalation)
Combination Product
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pharmacokinetic Study of Testosterone Enanthate

NCT01887418
View directory record Official record
Conditions
Hypogonadism
Interventions
QuickShot™ - 50 mg Treatment B, QuickShot™ - 100 mg Treatment A, Delatestryl 200 mg IM Treatment C
Drug
Lead sponsor
Antares Pharma Inc.
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Brookline, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Midazolam in Healthy Adults

NCT04679623
View directory record Official record
Conditions
Status Epilepticus
Interventions
Midazolam, Seizalam
Combination Product · Drug
Lead sponsor
Rafa Laboratories
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of Naloxone Pharmacokinetics

NCT03386591
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Naloxone, Mucosal atomization device and syringe, Narcan, Intramuscular Auto Injector
Drug · Device
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women

NCT02940522
View directory record Official record
Conditions
Comparing Bioavailability When Makena® is Administered in Healthy Post-menopausal Women
Interventions
Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 75 Years · Female only
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
5
States / cities
Anaheim, California • DeLand, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 25, 2026, 7:33 PM EDT